Related Experiment Videos
Combined lipid-lowering and antihypertensive treatment as part of a strategy of multiple risk factor intervention
N J Macdonald1, E Farish, S Stark
1University Department of Medicine, Stobhill General Hospital, Glasgow, UK.
Insights
Combined lipid-lowering and antihypertensive treatments effectively reduced total and LDL cholesterol by 30-40% without impacting blood pressure control. This dual intervention proved well-tolerated, suggesting a viable strategy for reducing cardiovascular disease risk.
Area of Science:
- Cardiology
- Pharmacology
- Metabolic Disorders
Background:
- Hypertension and hypercholesterolemia are significant cardiovascular disease risk factors.
- Managing both conditions simultaneously presents therapeutic challenges.
- Multiple risk factor intervention strategies are crucial for cardiovascular health.
Purpose of the Study:
- To evaluate the efficacy of combined lipid-lowering and antihypertensive treatment.
- To assess patient tolerability and compliance with dual therapy.
- To determine the impact on blood pressure and lipid profiles.
Main Methods:
- A 12-week study involving 36 patients with treated hypertension and hypercholesterolemia.
- Administration of combined lipid-lowering and antihypertensive medications.
- Monitoring of plasma lipid profiles, blood pressure, patient tolerability, and compliance.
Main Results:
- Significant reductions of 30-40% in total and LDL cholesterol were observed.
- Blood pressure control remained satisfactory (e.g., 144/82 mmHg supine).
- No significant changes in HDL cholesterol or Lp(a) were noted; patient tolerability and compliance were high.
Conclusions:
- Combined therapy effectively lowers LDL cholesterol without compromising blood pressure control.
- This approach offers a well-tolerated strategy for managing multiple cardiovascular risk factors.
- Substantial reductions in coronary heart disease (CHD) risk are achievable with this combined treatment.
Abstract:
Thirty-six patients with treated mild to moderate hypertension and hypercholesterolaemia (greater than 6.5 mmol/l) entered a 12 week study to evaluate the efficacy and patient tolerability of combined lipid-lowering and antihypertensive treatment as part of a strategy of multiple risk factor intervention. The principal effects on the plasma lipid profiles were significant reductions of 30-40% in total and LDL cholesterol. These reductions were achieved without loss of blood pressure control. There was no significant impact on HDL cholesterol or on lipoprotein Lp(a). These preliminary results suggest that substantial reductions in total and LDL cholesterol can be achieved without compromising blood pressure control which remained satisfactory at 144/82 supine and 143/80 mmHg standing. Furthermore, these changes were achieved without any problems of patient tolerability or interference with patient compliance with drug treatment. Overall, therefore, substantial reductions in CHD risk can be achieved with an acceptable combination of lipid lowering and antihypertensive treatments.